Pacira Pharmaceuticals (PCRX)
Create an AlertPacira Pharmaceuticals Enterprise Value:
960.17M for June 19, 2013Pacira Pharmaceuticals Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| June 19, 2013 | 960.17M |
| June 18, 2013 | 960.17M |
| June 17, 2013 | 970.08M |
| June 14, 2013 | 971.40M |
| June 13, 2013 | 985.61M |
| June 12, 2013 | 973.72M |
| June 11, 2013 | 972.72M |
| June 10, 2013 | 974.05M |
| June 7, 2013 | 959.18M |
| June 6, 2013 | 926.46M |
| June 5, 2013 | 940.67M |
| June 4, 2013 | 960.17M |
| June 3, 2013 | 975.70M |
| May 31, 2013 | 953.89M |
| May 30, 2013 | 976.03M |
| May 29, 2013 | 974.38M |
| May 28, 2013 | 964.46M |
| May 24, 2013 | 953.89M |
| May 23, 2013 | 968.10M |
| May 22, 2013 | 946.62M |
| May 21, 2013 | 938.69M |
| May 20, 2013 | 925.47M |
| May 17, 2013 | 958.51M |
| May 16, 2013 | 949.59M |
| May 15, 2013 | 952.24M |
| May 14, 2013 | 946.29M |
| May 13, 2013 | 946.29M |
| May 10, 2013 | 921.17M |
| May 9, 2013 | 895.39M |
| May 8, 2013 | 839.55M |
| May 7, 2013 | 877.88M |
| May 6, 2013 | 923.82M |
| May 3, 2013 | 943.31M |
| May 2, 2013 | 941.99M |
| May 1, 2013 | 898.37M |
| April 30, 2013 | 939.68M |
| April 29, 2013 | 941.33M |
| April 26, 2013 | 913.08M |
| April 25, 2013 | 928.24M |
| April 24, 2013 | 948.02M |
| April 23, 2013 | 970.43M |
| April 22, 2013 | 953.29M |
| April 19, 2013 | 927.25M |
| April 18, 2013 | 910.44M |
| April 17, 2013 | 957.90M |
| April 16, 2013 | 956.59M |
| April 15, 2013 | 938.13M |
| April 12, 2013 | 973.72M |
| April 11, 2013 | 951.31M |
| April 10, 2013 | 950.65M |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
PCRX Enterprise Value Benchmarks
| Companies | |
|---|---|
| Neurocrine Biosciences | 689.27M |
| Lannett Company | 315.35M |
| Abbott Laboratories | 55.89B |
PCRX Enterprise Value Rankings
| Overall |
80th percentile 3235 of 16782 |
| Sector |
83rd percentile 233 of 1410 in Healthcare |
| Industry |
80th percentile 26 of 135 in Drug Manufacturers - Major |
PCRX Enterprise Value Range, Past 5 Years
| Minimum | 85.58M | Apr 14 2011 |
| Maximum | 985.61M | Jun 13 2013 |
| Average | 373.40M |
